Newsletter

11/24/2015

Imaging3, Inc. Announces 2012-2013, 2103-2014, 10K’s completed.

Imaging3™, Inc. announces today that it has finalized and filed its 2012-13 and 2013-14 10Ks with the Securities and Exchange Commission. The company’s financials were audited by Rose, Snyder & Jacobs LLP, which is located in Encino, California.

We will now focus on completing all required quarterly financials and will make an announcement upon their completion.

Dane Medley, President and CEO of Imaging3, stated, “The completion of these annual financial reports is a great step in getting the company back on solid ground. It has taken a collaboration of many individuals and business partners working diligently towards the same goals. We are working on several other business initiatives that we hope will increase our revenues and bring value to our investors.”

About Imaging3 Imaging3, Inc., founded in 1993, has developed a medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to obtain a trading symbol from FINRA or to satisfy the other requirements for reemerging as a public company, failure to consummate desired business combinations or transactions, delays or adverse rulings relating to its Chapter 11 bankruptcy action, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company. Imaging3 cannot assure that it will obtain regulatory approval for its products, successfully complete the Chapter 11 bankruptcy process, or obtain a trading symbol from FINRA.

Contact:
Imaging3, Inc.
Investor Relations
951-283-5103